"Europeans find more gadolinium-related adverse reactions
Problems with gadolinium-containing contrast agents administered to patients with renal impairment are more common than originally estimated. The lack of awareness among radiologists about the potential dangers for those at high risk is striking, according to researchers. In June 2006, the FDA advised against giving gadolinium-containing contrast agents during MRI exams to patients with renal impairment. The warning came after the Danish Medicines Agency reported that 25 patients with kidney failure developed a life-threatening condition known as nephrogenic systemic fibrosis (NSF, previously known as nephrogenic fibrosing dermopathy). "
Reference- Diagnostic Imaging Online